C U Blank

List of Publications by Year
in descending order

163 papers	28,670 citations	18436 62 h-index	6979 154 g-index
168 all docs	168 docs citations	168 times ranked	31547 citing authors

#	Article	IF	Citations
1	Survival of stage IV melanoma in Belgium and the Netherlands. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	1
2	The unfavorable effects of <scp>COVID</scp>â€19 on Dutch advanced melanoma care. International Journal of Cancer, 2022, 150, 816-824.	2.3	18
3	Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. European Urology Open Science, 2022, 35, 54-58.	0.2	15
4	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	0.7	21
5	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	7.7	64
6	Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. Trials, 2022, 23, 137.	0.7	10
7	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surgery, 2022, 157, 335.	2.2	20
8	Clinical Models to Define Response and Survival With Antiâ€“PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	0.8	43
9	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. European Journal of Cancer, 2022, 167, 70-80.	1.3	19
10	Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Science Translational Medicine, 2022, 14, eabj9779.	5.8	18
11	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	15.2	121
12	Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Clinica Chimica Acta, 2022, 533, 71-78.	0.5	4
13	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 2021, 124, 574-580.	2.9	27
14	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administrationâ€”Melanoma Research Alliance Public Workshop. Clinical Cancer Research, 2021, 27, 394-401.	3.2	5
15	Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta OncolÃ³gica, 2021, 60, 69-77.	0.8	19
16	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 2021, 124, 1222-1230.	2.9	16
17	COVID-19 vaccination: the VOICE for patients with cancer. Nature Medicine, 2021, 27, 568-569.	15.2	53
18	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	15.2	218

#	Article	IF	Citations
19	Metabolic profiles of regulatory T cells in the tumour microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 2417-2427.	2.0	12
20	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature Medicine, 2021, 27, 256-263.	15.2	190
21	Reply to E. HindiÃ©. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
22	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. Annals of Surgery, 2021, 274, 383-389.	2.1	28
23	The prognostic value of the interferon-gamma (IFNÎ³) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy.. Journal of Clinical Oncology, 2021, 39, 9579-9579.	0.8	5
24	Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.. Journal of Clinical Oncology, 2021, 39, 9533-9533.	0.8	1
25	Is adjuvant treatment for melanoma in clinical practice comparable to trials? The first population-based results.. Journal of Clinical Oncology, 2021, 39, e21523-e21523.	0.8	0
26	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37
27	Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nationwide quality assurance in the Netherlands.. Journal of Clinical Oncology, 2021, 39, e18641-e18641.	0.8	0
28	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2021, 174, 641-648.	2.0	46
29	Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. Journal of Clinical Oncology, 2021, 39, 4573-4573.	0.8	1
30	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. European Journal of Cancer, 2021, 148, 51-57.	1.3	16
31	BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.. Journal of Clinical Oncology, 2021, 39, 9558-9558.	0.8	0
32	Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.. Journal of Clinical Oncology, 2021, 39, 9544-9544.	0.8	0
33	Dutch advanced melanoma care in times of COVID-19.. Journal of Clinical Oncology, 2021, 39, e21502-e21502.	0.8	1
34	Efficacy of checkpoint inhibition in advanced acral melanoma.. Journal of Clinical Oncology, 2021, 39, e21527-e21527.	0.8	0
35	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	5.1	224
36	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	5.1	104

#	Article	IF	Citations
37	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	1.7	11
38	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	0.6	22
39	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology, 2021, 32, 917-925.	0.6	76
40	Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4. Clinical Cancer Research, 2021, 27, 5389-5400.	3.2	3
41	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	1.3	12
42	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	15.2	159
43	Adjuvant treatment for melanoma in clinical practice â€“ Trial versus reality. European Journal of Cancer, 2021, 158, 234-245.	1.3	12
44	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 82-89.	0.6	2
45	Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	1.7	1
46	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1681-1691.	5.1	118
47	Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nature Communications, 2021, 12, 7348.	5.8	96
48	Phase Ib Study of Atezolizumab Plus Interferon-Î± with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology, 2021, 28, 5466-5479.	0.9	2
49	Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective singleâ€centre experience in patients with BRAFâ€mutated melanoma. Pigment Cell and Melanoma Research, 2020, 33, 498-506.	1.5	11
50	Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Research, 2020, 30, 252-260.	0.6	37
51	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. JAMA Oncology, 2020, 6, 519.	3.4	287
52	Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. Journal of Autoimmunity, 2020, 115, 102546.	3.0	13
53	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	0.6	132
54	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nature Medicine, 2020, 26, 1839-1844.	15.2	245

#	Article	IF	Citations
55	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
56	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. ESMO Open, 2020, 5, e000945.	2.0	14
57	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nature Communications, 2020, 11, 3946.	5.8	71
58	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. , 2020, 8, e000848.		79
59	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1449-1461.	0.6	69
60	Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach. , 2020, 8, e001352.		12
61	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of Clinical Oncology, 2020, 38, 3925-3936.	0.8	192
62	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ˜†. Annals of Oncology, 2020, 31, 1075-1082.	0.6	62
63	The human tumor microbiome is composed of tumor typeâ€“specific intracellular bacteria. Science, 2020, 368, 973-980.	6.0	1,077
64	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	13.7	1,421
65	Learning from clinical trials of neoadjuvant checkpoint blockade. Nature Medicine, 2020, 26, 475-484.	15.2	107
66	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1â€“Treated Patients in the Dutch Melanoma Treatment Registry. Clinical Cancer Research, 2020, 26, 2268-2274.	3.2	112
67	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. Journal of Clinical Oncology, 2020, 38, 10000-10000.	0.8	21
68	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. Journal of Clinical Oncology, 2020, 38, 10002-10002.	0.8	57
69	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. Journal of Clinical Oncology, 2020, 38, 10005-10005.	0.8	26
70	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.. Journal of Clinical Oncology, 2020, 38, 10015-10015.	0.8	18
71	Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.. Journal of Clinical Oncology, 2020, 38, TPS10087-TPS10087.	0.8	9
72	Prognostic and predictive role of the tumor immune landscape. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 143-151.	0.4	3

#	Article	IF	Citations
73	Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma. Journal of Cancer Research and Therapeutics, 2020, 16, 170.	0.3	0
74	Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report. Clinical and Experimental Rheumatology, 2020, 38, 1031-1032.	0.4	2
75	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell, 2019, 178, 585-599.e15.	13.5	162
76	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1239-1251.	5.1	812
77	Metastatic Uveal Melanoma: Treatment Strategies and Survivalâ€"Results from the Dutch Melanoma Treatment Registry. Cancers, 2019, 11, 1007.	1.7	22
78	A user's perspective on GeoMxTM digital spatial profiling. Immuno-Oncology Technology, 2019, 1, 11-18.	0.2	38
79	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
80	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open, 2019, 4, e000472.	2.0	26
81	Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. Cell Reports, 2019, 29, 135-150.e9.	2.9	189
82	Defining â€˜T cell exhaustionâ€™. Nature Reviews Immunology, 2019, 19, 665-674.	10.6	879
83	Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). European Urology, 2019, 76, 437-440.	0.9	29
84	Combining checkpoint inhibition and targeted therapy in melanoma. Nature Medicine, 2019, 25, 879-882.	15.2	15
85	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 948-960.	5.1	346
86	Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. Journal of Oncology, 2019, 2019, 1-17.	0.6	55
87	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2019, 116, 148-157.	1.3	64
88	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advancedNRAS- orBRAF-mutated melanoma. Oncotarget, 2019, 10, 1850-1859.	0.8	16
89	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine, 2019, 25, 920-928.	15.2	589
90	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clinical Cancer Research, 2019, 25, 5743-5751.	3.2	129

#	Article	IF	Citations
91	Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Annals of Oncology, 2019, 30, 998-1004.	0.6	361
92	Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. British Journal of Surgery, 2019, 106, 519-522.	0.1	35
93	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. OncoImmunology, 2019, 8, 1558664.	2.1	0
94	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology, 2019, 30, 1154-1161.	0.6	170
95	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine, 2019, 25, 1916-1927.	15.2	541
96	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell, 2019, 176, 775-789.e18.	13.5	760
97	Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. OncoImmunology, 2019, 8, e1546068.	2.1	42
98	Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. JAMA Oncology, 2019, 5, 164.	3.4	329
99	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology, 2019, 75, 435-444.	0.9	97
100	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Journal of Clinical Oncology, 2019, 37, 9503-9503.	0.8	34
101	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	0.8	16
102	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801.	13.9	1,441
103	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open, 2018, 3, e000278.	2.0	197
104	Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Melanoma Research, 2018, 28, 126-133.	0.6	31
105	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine, 2018, 24, 203-212.	15.2	178
106	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. American Journal of Clinical Dermatology, 2018, 19, 303-317.	3.3	78
107	Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nature Medicine, 2018, 24, 1655-1661.	15.2	599
108	Targeting tumor-associated acidity in cancer immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1331-1348.	2.0	55

#	Article	IF	Citations
109	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	0.6	135
110	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. Journal of Clinical Oncology, 2018, 36, 9503-9503.	0.8	71
111	Open-label, multicentre safety study of vemurafenib inÂ3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	1.3	31
112	Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. Acta OncolÃ³gica, 2017, 56, 101-103.	0.8	39
113	Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature, 2017, 550, 270-274.	13.7	138
114	Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Annals of Oncology, 2017, 28, 862-867.	0.6	13
115	Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma. Urology, 2017, 109, 127-133.	0.5	8
116	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 2017, 549, 106-110.	13.7	501
117	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. Journal of Clinical Oncology, 2017, 35, 9504-9504.	0.8	53
118	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. Journal of Clinical Oncology, 2017, 35, 9539-9539.	0.8	4
119	Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. Journal of Clinical Oncology, 2017, 35, 9586-9586.	0.8	23
120	Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. International Journal of Molecular Sciences, 2016, 17, 2149.	1.8	2
121	Proportions of blood-borne VÎ´1+ and VÎ´2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer, 2016, 64, 116-126.	1.3	54
122	Systematic review of the use of granulocyteâ€“macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2016, 65, 1015-1034.	2.0	49
123	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports, 2016, 16, 263-277.	2.9	61
124	Biomarkers for outcome upon MAPK inhibition in melanoma. Lancet Oncology, The, 2016, 17, 1634-1636.	5.1	0
125	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunology, Immunotherapy, 2016, 65, 753-763.	2.0	32
126	The â€œcancer immunogramâ€• Science, 2016, 352, 658-660.	6.0	655

#	Article	IF	Citations
127	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology, 2016, 5, e1238557.	2.1	113
128	Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Annals of Oncology, 2016, 27, 1138-1142.	0.6	68
129	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016, 22, 2155-2166.	3.2	211
130	Intraâ€•and interâ€tumor heterogeneity in a vemurafenibâ€resistant melanoma patient and derived xenografts. EMBO Molecular Medicine, 2015, 7, 1104-1118.	3.3	129
131	Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression. European Journal of Cancer, 2015, 51, 642-652.	1.3	30
132	Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunology, Immunotherapy, 2015, 64, 1241-1250.	2.0	98
133	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, The, 2015, 16, 908-918.	5.1	1,419
134	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	13.9	4,838
135	Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. Seminars in Oncology, 2015, 42, 423-428.	0.8	55
136	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Molecular Therapy, 2015, 23, 1541-1550.	3.7	93
137	Therapeutic use of anti-CTLA-4 antibodies. International Immunology, 2015, 27, 3-10.	1.8	96
138	The perspective of immunotherapy. Current Opinion in Oncology, 2014, 26, 204-214.	1.1	64
139	Interferonâ€induced programmed deathâ€ligand 1 (<scp>PD</scp>â€<scp>L</scp>1/<scp>B</scp>7â€<scp>H</scp>1) expression increases on human acute myeloid leukemia blast cells during treatment. European Journal of Haematology, 2014, 92, 195-203.	1.1	92
140	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 449-58.	2.0	253
141	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	5.1	242
142	Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts. Cancer Immunology, Immunotherapy, 2013, 62, 503-515.	2.0	10
143	High-throughput identification of antigen-specific TCRs by TCR gene capture. Nature Medicine, 2013, 19, 1534-1541.	15.2	166
144	The effect of seasonal variation and secretion of sunitinib in sweat on the development of handâ€“foot syndrome. European Journal of Clinical Pharmacology, 2013, 69, 2065-2072.	0.8	7

#	Article	IF	Citations
145	Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta OncolÃ³gica, 2013, 52, 1786-1788.	0.8	67
146	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, The, 2013, 14, 249-256.	5.1	587
147	Neurological immune-related adverse events of ipilimumab. Practical Neurology, 2013, 13, 278-280.	0.5	120
148	Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab. Clinical Nuclear Medicine, 2013, 38, e182-e184.	0.7	38
149	Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. OncoTargets and Therapy, 2013, 6, 1649.	1.0	11
150	Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission. Journal of Clinical Oncology, 2012, 30, e7-e10.	0.8	119
151	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. OncoImmunology, 2012, 1, 609-617.	2.1	67
152	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2012, 380, 358-365.	6.3	2,691
153	Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. Journal of Neurology, 2012, 259, 1976-1978.	1.8	59
154	Targeting BRAF in an Inducible Murine Model of Melanoma. American Journal of Pathology, 2012, 181, 785-794.	1.9	58
155	Reduced tumorâ€antigen density leads to PDâ€1/PDâ€L1â€mediated impairment of partially exhausted CD8⁺ T cells. European Journal of Immunology, 2012, 42, 662-671.	1.6	17
156	Immunological Heterogeneity of the RCC Microenvironment: Do Targeted Therapies Influence Immune Response?. Current Oncology Reports, 2012, 14, 230-239.	1.8	11
157	Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunology, Immunotherapy, 2011, 60, 1359-1371.	2.0	40
158	Nonâ€“Clear Cell Renal Cell Carcinoma: How New Biological Insight May Lead to New Therapeutic Modalities. Current Oncology Reports, 2011, 13, 240-248.	1.8	14
159	Overall survival and PDâ€L1 expression in metastasized malignant melanoma. Cancer, 2011, 117, 2192-2201.	2.0	204
160	Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient. Journal of Analytical Toxicology, 2011, 35, 558-565.	1.7	33
161	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunology, Immunotherapy, 2010, 59, 1173-1183.	2.0	47
162	Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Review of Dermatology, 2009, 4, 67-78.	0.3	61

#	Article	IF	Citations
163	Homeostatic proliferation of naÃ¯ve CD8⁺ T cells depends on CD62L/Lâ€selectinâ€mediated homing to peripheral LN. European Journal of Immunology, 2009, 39, 2981-2990.	1.6	16